Recruiting studies: Ovarian Epithelial Cancer Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cance
NA · 1 location(s) · Chang Gung Memorial Hospital · NCT06232122 Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Phase 1/Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06040970 ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Phase 1/Phase 2 · 21 location(s) · Immatics US, Inc. · NCT03686124 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2 · 17 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06434610 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT05950464 Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Phase 2 · 2 location(s) · Tel-Aviv Sourasky Medical Center · NCT06839144 A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064 RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06420973 Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Phase N/A · 1 location(s) · University of Washington · NCT06295965 CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Phase 1 · 1 location(s) · Lan Coffman · NCT05942300 HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2 · 28 location(s) · Hansoh BioMedical R&D Company · NCT06014190 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ova
Phase 1/Phase 2 · 52 location(s) · Regeneron Pharmaceuticals · NCT03564340 Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05316129 Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-
Phase 2 · 2 location(s) · Jiangsu Cancer Institute & Hospital · NCT07311577 Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
NA · 1 location(s) · CNAO National Center of Oncological Hadrontherapy · NCT05457595 CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05410717 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 482 location(s) · National Cancer Institute (NCI) · NCT05564377 A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Com
Phase 2 · 2 location(s) · ImmunityBio, Inc. · NCT06710288 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471 Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Pro
NA · 1 location(s) · The First Hospital of Jilin University · NCT07495384 MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurre
Phase 3 · 1 location(s) · National Cancer Institute, Naples · NCT05255471 IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment
Phase 2 · 1 location(s) · InxMed (Shanghai) Co., Ltd. · NCT06014528 Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589543 Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05753826 APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480954 BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1 · 4 location(s) · Bio-Path Holdings, Inc. · NCT04196257 Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07540403 Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Can
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07144826 A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Phase 1/Phase 2 · 28 location(s) · Compugen Ltd · NCT06888921

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →